Judge’s unusual ruling on Amgen, Regeneron patent case puts billions of dollars at stake
January 06, 2017 at 12:17 PM EST
The decision could force Regeneron/Sanofi to stop selling their $14,000-a-year Praluent drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|